First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) ...
A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...
Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...
Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback